Compare RCUS & QFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RCUS | QFIN |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.5B |
| IPO Year | 2018 | 2018 |
| Metric | RCUS | QFIN |
|---|---|---|
| Price | $23.08 | $16.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 2 |
| Target Price | $28.89 | ★ $36.85 |
| AVG Volume (30 Days) | 1.4M | ★ 1.4M |
| Earning Date | 02-24-2026 | 11-18-2025 |
| Dividend Yield | N/A | ★ 9.03% |
| EPS Growth | N/A | ★ 40.93 |
| EPS | N/A | ★ 6.93 |
| Revenue | $240,000,000.00 | ★ $2,752,357,572.00 |
| Revenue This Year | N/A | $16.96 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $2.43 |
| Revenue Growth | N/A | ★ 14.06 |
| 52 Week Low | $6.50 | $16.20 |
| 52 Week High | $26.40 | $48.94 |
| Indicator | RCUS | QFIN |
|---|---|---|
| Relative Strength Index (RSI) | 52.59 | 32.52 |
| Support Level | $20.70 | $16.20 |
| Resistance Level | $23.40 | $17.13 |
| Average True Range (ATR) | 1.44 | 0.69 |
| MACD | 0.03 | -0.11 |
| Stochastic Oscillator | 61.75 | 15.11 |
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Qfin Holdings Inc Formerly Qifu Technology Inc is a Credit-Tech platform in China. It provides credit services more accessible and personalized to consumers and SMEs through Credit-Tech services to financial institutions, whereby it deploys its technology solutions to help financial institutions identify the diversified needs of consumers and SMEs, effectively access prospective borrowers that are creditworthy through multi-channels, enhance credit assessment on prospective borrowers, and manage credit risks and improve collection strategies and efficiency, among others.